Literature DB >> 2528941

Treatment of Clostridium difficile-associated disease with teicoplanin.

F de Lalla1, G Privitera, E Rinaldi, G Ortisi, D Santoro, G Rizzardini.   

Abstract

Forty-seven patients affected by Clostridium difficile-associated disease were treated orally with either vancomycin (patients hospitalized from February 1984 to February 1987) or teicoplanin (from March 1987 to December 1988). All patients given teicoplanin remained asymptomatic after discontinuation of treatment, and all but one were also cleared of C. difficile. In the vancomycin group, clinical symptoms recurred in 3 of 23 evaluable patients, and follow-up cultures were positive in another asymptomatic case.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528941      PMCID: PMC176077          DOI: 10.1128/AAC.33.7.1125

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Parenteral therapy for antibiotic-associated pseudomembranous colitis.

Authors:  D I Kleinfeld; R J Sharpe; S T Donta
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

2.  Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria.

Authors:  V L Sutter; A L Barry; T D Wilkins; R J Zabransky
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

3.  Isolation of Clostridium difficile from patients and the environment of hospital wards.

Authors:  H Malamou-Ladas; S O'Farrell; J Q Nash; S Tabaqchali
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

4.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

5.  Oral vancomycin for antibiotic-associated pseudomembranous colitis.

Authors:  F Tedesco; R Markham; M Gurwith; D Christie; J G Bartlett
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

6.  Antibiotic-associated colitis: effects of antibiotics on Clostridium difficile and the disease in hamsters.

Authors:  R Fekety; J Silva; R Toshniwal; M Allo; J Armstrong; R Browne; J Ebright; G Rifkin
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

7.  Metronidazole: an alternate therapy for antibiotic-associated colitis.

Authors:  R D Cherry; D Portnoy; M Jabbari; D S Daly; D G Kinnear; C A Goresky
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

8.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions.

Authors:  W L George; R D Rolfe; S M Finegold
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

10.  Recent advances in management of bacterial diarrhea.

Authors:  R Fekety
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr
View more
  10 in total

Review 1.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 2.  Update on pseudomembranous colitis.

Authors:  J Silva
Journal:  West J Med       Date:  1989-12

3.  Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.

Authors:  Natasa Popovic; Milos Korac; Zorica Nesic; Branko Milosevic; Aleksandar Urosevic; Djordje Jevtovic; Nikola Mitrovic; Aleksandar Markovic; Jelena Jordovic; Natasa Katanic; Aleksandra Barac; Ivana Milosevic
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-03       Impact factor: 3.267

4.  Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery.

Authors:  G Privitera; P Scarpellini; G Ortisi; G Nicastro; R Nicolin; F de Lalla
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

Review 5.  Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D M Campoli-Richards; R N Brogden; D Faulds
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 6.  The clinical significance of antibiotic-associated pseudomembranous colitis in the 1990s.

Authors:  M Andréjak; J L Schmit; A Tondriaux
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

7.  Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma.

Authors:  Kenichi Nomura; Yosuke Matsumoto; Naohisa Yoshida; Sawako Taji; Naoki Wakabayashi; Shoji Mitsufuji; Shigeo Horiike; Masuji Morita; Takeshi Okanoue; Masafumi Taniwaki
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

8.  In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.

Authors:  F Biavasco; E Manso; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

9.  Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea.

Authors:  F de Lalla; R Nicolin; E Rinaldi; P Scarpellini; R Rigoli; V Manfrin; A Tramarin
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

Review 10.  A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.

Authors:  Csaba Fehér; Alex Soriano; Josep Mensa
Journal:  Infect Dis Ther       Date:  2016-12-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.